• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeritas touts h-Patch CBD study

September 24, 2019 By Danielle Kirsh

ValeritasValeritas (NSDQ:VLRX) today announced positive results from its preclinical pharmacokinetic study of cannabidiol subcutaneous infusion.

The study focused on delivering cannabidiol (CBD) through subcutaneous infusion through the company’s h-Patch Wearable Device. The results were presented at the CannMed Conference in Pasadena, Calif.

Results from the study showed rapid and robust absorption and distribution of 40mg of CBD delivered over a 24 hour period using the h-Patch technology. Researchers detected CBD within one hour of the start of infusion followed by prolonged elimination with near steady-state levels that were detected 24 hours after infusion and 48 hours in total.

Peak plasma levels were equal to published human dose-normalized plasma concentrations from single oral administration of 300mg of CBD, resulting in an 87% reduction of CBD dosage.

“The study demonstrates our h-Patch technology has the potential of dramatically lowering the overall amount of CBD needed to achieve therapeutic levels while providing reliable and uniform dosing,” president & CEO John Timberlake said in a news release.

The h-Patch is a drug delivery technology that delivers injectable medicines subcutaneously. Oral CBD has very low bioavailability in humans in a range of 6-10%, according to the company. One reported concern is the long-term effect CBD can have on the liver from exposure to toxic metabolites. Valeritas said that the h-Patch provides a continuous basal delivery rate over a period of 24 hours.

Subcutaneous infusion of CBD through the h-Patch enables a prolonged half-life, minimization of the variation in CBD metabolism and reduces the amount of drug metabolized by the liver as opposed to oral dosage, according to the company.

Filed Under: Drug-Device Combinations Tagged With: CBD, Valeritas Inc.

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS